IDRx Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 45

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.15B

IDRx General Information

Description

Developer of oncology-based precision therapies intended to revolutionize the treatment of cancer. The company designs precision combination therapies, medicines with highly selective, engineered drug combinations to stop key tumor escape mechanisms and prolong response to therapy, enabling healthcare professionals to develop cancer medicines for patients through intentionally built treatment combinations.

Contact Information

Website
www.idrx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 52A Court Street
  • Plymouth, MA 02360
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
GSK
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 52A Court Street
  • Plymouth, MA 02360
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IDRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 21-Feb-2025 $1.15B Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 05-Aug-2024 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 28-Apr-2022 $122M $122M Completed Clinical Trials - Phase 1
To view IDRx’s complete valuation and funding history, request access »

IDRx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A-2
Series A-1 21,410,917 $0.000010 8% $6.1 $6.1 1x $6.1 32.07%
To view IDRx’s complete cap table history, request access »

IDRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oncology-based precision therapies intended to revolutionize the treatment of cancer. The company designs p
Drug Discovery
Plymouth, MA
45 As of 2025

Gaithersburg, MD
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IDRx Competitors (6)

One of IDRx’s 6 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Kite Pharma Formerly VC-backed Santa Monica, CA
Kura Oncology Formerly VC-backed San Diego, CA
Getwell Oncology Corporation Gurugram, India
Mustang Bio Formerly VC-backed Waltham, MA
To view IDRx’s complete competitors history, request access »

IDRx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IDRx Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andreessen Horowitz Venture Capital Minority
B-Flexion Advisors PE/Buyout Minority
Blackstone PE/Buyout Minority
Blueprint Medicines Corporation Minority
Borisy Labs Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

IDRx FAQs

  • When was IDRx founded?

    IDRx was founded in 2021.

  • Where is IDRx headquartered?

    IDRx is headquartered in Plymouth, MA.

  • What is the size of IDRx?

    IDRx has 45 total employees.

  • What industry is IDRx in?

    IDRx’s primary industry is Drug Discovery.

  • Is IDRx a private or public company?

    IDRx is a Private company.

  • What is the current valuation of IDRx?

    The current valuation of IDRx is .

  • What is IDRx’s current revenue?

    The current revenue for IDRx is .

  • How much funding has IDRx raised over time?

    IDRx has raised $242M.

  • Who are IDRx’s investors?

    Andreessen Horowitz, B-Flexion Advisors, Blackstone, Blueprint Medicines, and Borisy Labs are 5 of 12 investors who have invested in IDRx.

  • Who are IDRx’s competitors?

    NexImmune, Kite Pharma, Kura Oncology, Getwell Oncology, and Mustang Bio are some of the 6 competitors of IDRx.

  • When was IDRx acquired?

    IDRx was acquired on 21-Feb-2025.

  • Who acquired IDRx?

    IDRx was acquired by GSK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »